On this page
Mitchell-Riley syndrome
This syndrome is characterised by neonatal diabetes, issues with the exocrine function of the pancreas, and problems with the development and rotation of the intestines. It is a severe condition that becomes apparent shortly after birth.
Overview
Mitchell-Riley syndrome is a complex, very rare genetic condition that affects multiple body systems, most notably the pancreas and the gastrointestinal tract. Individuals with this syndrome are typically diagnosed in the neonatal period, meaning within the first month of life. Key features often include neonatal diabetes, which is a form of diabetes that develops very early in life, and exocrine pancreatic insufficiency, where the pancreas struggles to produce enzymes needed for digestion [PMID:24074213].
Beyond pancreatic issues, Mitchell-Riley syndrome is also associated with intestinal malrotation, a condition where the intestines do not form or position correctly during development. This can lead to serious digestive problems. The overall presentation can vary, but the combination of these features is characteristic of the syndrome. Due to its rarity, understanding of the full spectrum of symptoms is still evolving [PMID:22033282].
Symptoms & clinical features
The symptoms of Mitchell-Riley syndrome typically become apparent very soon after birth. Neonatal diabetes is a consistent feature, presenting with high blood sugar levels that require medical intervention. Alongside this, exocrine pancreatic insufficiency can lead to difficulties absorbing nutrients from food, resulting in poor weight gain and often foul-smelling, fatty stools (steatorrhoea).
Intestinal malrotation can cause severe digestive problems, including abdominal pain, vomiting, and blockages, which may require surgical correction. Some individuals may also experience other anomalies such as gallbladder agenesis (absence of the gallbladder) or hypoplasia (underdevelopment of the gallbladder) [PMID:22033282]. While these are the most commonly reported features, the severity and exact combination of symptoms can differ between affected individuals.
Video: Genetics 101
Affected organs
The primary organs affected in Mitchell-Riley syndrome are the pancreas and the gastrointestinal tract. The pancreas is involved in two main ways: its endocrine function (producing hormones like insulin for blood sugar regulation) is impaired, leading to diabetes, and its exocrine function (producing digestive enzymes) is also compromised. The intestines are affected by malrotation, meaning they are not positioned correctly within the abdomen, which can impede their normal function. Other digestive organs, such as the gallbladder, may also be absent or underdeveloped in some cases.
Risks & severity
Mitchell-Riley syndrome is considered a severe condition, often presenting with significant health challenges from birth. The presence of neonatal diabetes requires lifelong management, and exocrine pancreatic insufficiency necessitates enzyme replacement therapy and nutritional support. Intestinal malrotation can be life-threatening if not surgically corrected, due to the risk of intestinal blockage or twisting.
While exact prevalence figures are not well established due to its extreme rarity, the condition typically leads to substantial medical needs in infancy. The long-term prognosis is dependent on the severity of symptoms and the effectiveness of medical and surgical interventions. There is a range in how severely individuals are affected, but comprehensive support is generally required.
Genetic causes
Mitchell-Riley syndrome is caused by pathogenic variants in the *RFX6* gene. This gene provides instructions for making a protein called Regulatory Factor X6. The RFX6 protein plays a crucial role as a transcription factor, which means it helps control the activity of other genes [PMID:24074213].
Specifically, RFX6 is vital for the proper development of the pancreas, including the cells that produce insulin and digestive enzymes, and for the normal formation of the gastrointestinal tract. When there are pathogenic changes in the *RFX6* gene, the RFX6 protein may not function correctly or may be absent. This disruption impairs the development and function of these organs, leading to the characteristic features of Mitchell-Riley syndrome [PMID:22033282].
- RFX6 regulatory factor X6
Inheritance pattern
Mitchell-Riley syndrome has an autosomal recessive inheritance pattern. This means that a child will only develop the condition if they inherit two altered copies of the *RFX6* gene - one from each parent. Individuals who have only one altered copy of the gene are known as carriers. Carriers typically do not show any symptoms of the condition themselves because their other unaffected copy of the gene can compensate.
When two carriers of an *RFX6* gene variant have children, there is a 25% (1 in 4) chance with each pregnancy that their child will inherit two altered copies and thus be affected by Mitchell-Riley syndrome. There is also a 50% (1 in 2) chance that their child will be a carrier like them, and a 25% chance that their child will inherit two normal copies of the gene.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
The diagnosis of Mitchell-Riley syndrome is typically suspected based on the characteristic clinical features observed in a newborn, such as neonatal diabetes, signs of pancreatic insufficiency, and intestinal anomalies. Confirmation of the diagnosis is made through genetic testing, which looks for pathogenic variants in the *RFX6* gene.
Genetic testing for suspected Mitchell-Riley syndrome would typically be carried out via an NHS Genomic Medicine Service (GMS) approved laboratory, often following a referral from a paediatrician or endocrinologist to a clinical genetics service. This testing falls under specific NHS national genomic test directory R-codes, allowing for targeted sequencing of the *RFX6* gene or broader genomic approaches like whole exome sequencing, to identify the underlying genetic cause. Genetic counselling is an important part of the diagnostic pathway to help families understand the condition and its inheritance.
Management & lifestyle
Management of Mitchell-Riley syndrome is supportive and focuses on addressing the specific symptoms and complications. Neonatal diabetes requires careful insulin management to control blood sugar levels. Exocrine pancreatic insufficiency is managed with pancreatic enzyme replacement therapy, taken with meals, to aid digestion and nutrient absorption. Nutritional support is also crucial, often including dietary adjustments or supplemental feeding.
Intestinal malrotation may require surgical intervention to correct the anatomical abnormalities and prevent complications like blockages or twisting of the bowel. Regular monitoring by a multidisciplinary team, including paediatric endocrinologists, gastroenterologists, and surgeons, is essential to manage the various aspects of the syndrome. Genetic counsellors provide ongoing support to families, helping them understand the genetic basis and implications for future pregnancies.
UK care pathway
In the UK, individuals suspected of having genetic conditions like Mitchell-Riley syndrome are typically referred to an NHS clinical genetics service. These specialist services can arrange for appropriate genetic testing, often through the NHS Genomic Medicine Service (GMS) laboratories. Genetic testing for conditions like Mitchell-Riley syndrome is usually covered by specific R-codes within the national genomic test directory. Following diagnosis, individuals and families will be supported by a genetic counsellor, who can provide information about the condition, its inheritance, and implications for family planning, and help coordinate care with other specialist teams.
Frequently asked questions
What is neonatal diabetes?
Neonatal diabetes is a rare form of diabetes that is diagnosed within the first six months of life. Unlike type 1 or type 2 diabetes, it is often caused by specific genetic changes that affect the pancreas's ability to produce insulin from birth.
Can Mitchell-Riley syndrome be passed down to children?
Yes, Mitchell-Riley syndrome is inherited in an autosomal recessive pattern. This means that if both parents are carriers of a pathogenic *RFX6* gene variant, there is a 1 in 4 chance that each of their children will inherit the condition.
How is Mitchell-Riley syndrome diagnosed?
Diagnosis is typically made based on clinical symptoms observed shortly after birth, such as neonatal diabetes and digestive problems. It is confirmed by genetic testing that identifies pathogenic changes in the *RFX6* gene.
What kind of doctors treat Mitchell-Riley syndrome?
Individuals with Mitchell-Riley syndrome are typically cared for by a team of specialists, which may include paediatric endocrinologists, gastroenterologists, surgeons, dietitians, and clinical geneticists, often coordinated by a genetic counsellor.
Is there a cure for Mitchell-Riley syndrome?
Currently, there is no cure for Mitchell-Riley syndrome. Treatment focuses on managing the symptoms and complications, such as insulin therapy for diabetes, enzyme replacement for pancreatic insufficiency, and surgical correction for intestinal issues, to improve quality of life.
References
- Passone CGB, Vermillac G, Staels W. Mitchell-Riley Syndrome: Improving Clinical Outcomes and Searching for Functional Impact of RFX-6 Mutations. Frontiers in endocrinology. 2022. PMID: 35813646
- Estefanía-Fernández K, Andrés A, Alcolea A. First multivisceral transplantation in Mitchell-Riley/Martinez-Frias syndrome. Pediatric transplantation. 2022. PMID: 35307919
- Cruz L, Schnur RE, Post EM. Clinical and genetic complexity of Mitchell-Riley/Martinez-Frias syndrome. Journal of perinatology : official journal of the California Perinatal Association. 2014. PMID: 25421130
- Ibrahim H, Balboa D, Saarimäki-Vire J. RFX6 haploinsufficiency predisposes to diabetes through impaired beta cell function. Diabetologia. 2024. PMID: 38743124
- Trott J, Alpagu Y, Tan EK. Mitchell-Riley syndrome iPSCs exhibit reduced pancreatic endoderm differentiation due to a mutation in RFX6. Development (Cambridge, England). 2020. PMID: 33033118
- Zegre Amorim M, Houghton JA, Carmo S. Mitchell-Riley Syndrome: A Novel Mutation in RFX6 Gene. Case reports in genetics. 2015. PMID: 26770845
- Sá B, Girbal I, Espírito-Santo AR. Dual genetic diagnosis of Mitchell-Riley syndrome and Temple syndrome in a neonate. Clinical dysmorphology. 2025. PMID: 40445129
- Calcaterra V, Chiricosta L, Mazzon E. Determining oncogenic patterns and cancer predisposition through the transcriptomic profile in Mitchell-Riley syndrome with heterotopic gastric mucosa and duodenal atresia: a case report. Orphanet journal of rare diseases. 2021. PMID: 34715892